Skip to content
10-Q

Quarterly Report

Rapid Therapeutic Science Laboratories, Inc.

0001393905-21-000369

← back to feed
Filed
Aug 11, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2021 · Aug 11, 2021 193.54M sh
Cash And Equivalents Q2 2021 · Jun 30, 2021 $47.92K
Cash And Equivalents Q2 2021 · Dec 31, 2020 $499.15K
Cash And Equivalents Q2 2021 · Jun 30, 2020 $213.12K
Cash And Equivalents Q2 2021 · Dec 31, 2019 $125.13K
Stockholders Equity Q2 2021 · Jun 30, 2021 $396.49K
Stockholders Equity Q2 2021 · Dec 31, 2020 −$11.2K
Current Liabilities Q2 2021 · Jun 30, 2021 $466.52K
Current Liabilities Q2 2021 · Dec 31, 2020 $1.21M
Total Liabilities Q2 2021 · Jun 30, 2021 $616.52K
Total Liabilities Q2 2021 · Dec 31, 2020 $1.52M
Current Assets Q2 2021 · Jun 30, 2021 $214.72K
Current Assets Q2 2021 · Dec 31, 2020 $685.95K
Total Assets Q2 2021 · Jun 30, 2021 $1.01M
Total Assets Q2 2021 · Dec 31, 2020 $1.51M
Capex Q2 2021 · Jun 30, 2020 $0
Sga Expense Q2 2021 · Jun 30, 2020 $629.51K
Sga Expense Q2 2021 · Jun 30, 2020 $853.75K
Net Income Q2 2021 · Jun 30, 2020 −$566.38K
Net Income Q2 2021 · Jun 30, 2020 −$877.53K
Net Income Q2 2021 · Mar 31, 2020 −$311.15K
Gross Profit Q2 2021 · Jun 30, 2020 $110.73K
Gross Profit Q2 2021 · Jun 30, 2020 $112.72K
Cost Of Revenue Q2 2021 · Jun 30, 2020 $18.56K
Cost Of Revenue Q2 2021 · Jun 30, 2020 $25.71K
Revenue Q2 2021 · Jun 30, 2020 $129.29K
Revenue Q2 2021 · Jun 30, 2020 $138.43K